From the point of view of therapy, finding germline variants in these proteins is also relevant, e.g., recent results indicate that BRCA1/2 testing helps design the treatment strategy for breast and ovarian cancer patients [3,4,6]. This evidence concerns the gene BRCA1 and ovarian cancer.